219 related articles for article (PubMed ID: 34504198)
21. Unraveling the complexities of drug reaction with eosinophilia and systemic symptoms (DRESS): Insights into clinical, laboratory, and histopathologic features of a case series from an Italian tertiary center.
Schroeder JW; Napoli C; Caputo V; Bonoldi E; Rongioletti F
Clin Dermatol; 2023; 41(6):721-728. PubMed ID: 37730074
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic management of DRESS: a retrospective study of 38 cases.
Funck-Brentano E; Duong TA; Bouvresse S; Bagot M; Wolkenstein P; Roujeau JC; Chosidow O; Valeyrie-Allanore L
J Am Acad Dermatol; 2015 Feb; 72(2):246-52. PubMed ID: 25592341
[TBL] [Abstract][Full Text] [Related]
23. Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review.
de Filippis R; Soldevila-Matías P; Guinart D; De Fazio P; Rubio JM; Kane JM; Schoretsanitis G
J Psychopharmacol; 2021 Sep; 35(9):1062-1073. PubMed ID: 34044659
[TBL] [Abstract][Full Text] [Related]
24. Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature, with a focus on relapsing cases.
Afiouni R; Zeinaty P; Kechichian E; Zoghaib S; Matar S; Helou-Mallat J; Tomb R
Pediatr Dermatol; 2021 Jan; 38(1):125-131. PubMed ID: 33155729
[TBL] [Abstract][Full Text] [Related]
25. Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases.
Kridin K; Brüggen MC; Walsh S; Bensaid B; Ranki A; Oppel E; Meyersburg D; Chua SL; Seeli C; Sandberg H; French LE; Vorobyev A; Ingen-Housz-Oro S
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):753-762. PubMed ID: 36479739
[TBL] [Abstract][Full Text] [Related]
26. Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: A prospective case-control study.
Choudhary R; Vinay K; Srivastava N; Bishnoi A; Kamat D; Parsad D; Bhatia A; Kumaran MS
J Am Acad Dermatol; 2021 Oct; 85(4):901-909. PubMed ID: 33785387
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome.
Sim DW; Yu J; Koh YI
Clin Transl Sci; 2022 Mar; 15(3):782-788. PubMed ID: 34796665
[TBL] [Abstract][Full Text] [Related]
28. A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature.
Zhang Y; Wang X; Cheng Y; Wang X; Zhang Y
BMC Pulm Med; 2022 Jul; 22(1):279. PubMed ID: 35854287
[TBL] [Abstract][Full Text] [Related]
29. Drug reaction with eosinophilia and systemic symptoms (DRESS): A histopathology based analysis.
Sasidharanpillai S; Govindan A; Riyaz N; Binitha MP; Muhammed K; Khader A; Reena Mariyath OK; Simin M; Subin K
Indian J Dermatol Venereol Leprol; 2016; 82(1):28-36. PubMed ID: 26728807
[TBL] [Abstract][Full Text] [Related]
30. Drug reaction with eosinophilia and systemic symptoms syndrome is not uncommon and shows better clinical outcome than generally recognised.
Nam YH; Park MR; Nam HJ; Lee SK; Kim KH; Roh MS; Um SJ; Son CH
Allergol Immunopathol (Madr); 2015; 43(1):19-24. PubMed ID: 24388810
[TBL] [Abstract][Full Text] [Related]
31. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease.
Mizukawa Y; Hirahara K; Kano Y; Shiohara T
J Am Acad Dermatol; 2019 Mar; 80(3):670-678.e2. PubMed ID: 30240780
[TBL] [Abstract][Full Text] [Related]
32. Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature.
Metterle L; Hatch L; Seminario-Vidal L
Pediatr Dermatol; 2020 Jan; 37(1):124-129. PubMed ID: 31691347
[TBL] [Abstract][Full Text] [Related]
33. Shock state: an unrecognized and underestimated presentation of drug reaction with eosinophilia and systemic symptoms.
Kimmoun A; Dubois E; Perez P; Barbaud A; Levy B
Shock; 2013 Nov; 40(5):387-91. PubMed ID: 24088996
[TBL] [Abstract][Full Text] [Related]
34. How to recognize and manage challenging DRESS cases: Two case reports and a review of the literature.
Ak T; Erdem S; Durmus RB; Kimyon U; Engin B; Bavunoglu I
Dermatol Ther; 2022 Nov; 35(11):e15785. PubMed ID: 35997939
[TBL] [Abstract][Full Text] [Related]
35. Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine.
Torroba Sanz B; Mendez Martínez E; Cacho Asenjo E; Aquerreta Gonzalez I
Eur J Hosp Pharm; 2021 Sep; 28(5):285-288. PubMed ID: 34426483
[TBL] [Abstract][Full Text] [Related]
36. Drug Reaction with Eosinophilia and Systemic Symptoms: Retrospective Analysis of 104 Cases over One Decade.
Wang L; Mei XL
Chin Med J (Engl); 2017 Apr; 130(8):943-949. PubMed ID: 28397724
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS).
Yang F; Chen SA; Wu X; Zhu Q; Luo X
Eur J Dermatol; 2018 Feb; 28(1):13-25. PubMed ID: 29521632
[TBL] [Abstract][Full Text] [Related]
38. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome.
Kim DH; Koh YI
Allergy Asthma Immunol Res; 2014 May; 6(3):216-21. PubMed ID: 24843796
[TBL] [Abstract][Full Text] [Related]
39. Trimethoprim-Sulfamethoxazole-Induced Drug Eruption With Eosinophilia and Systemic Symptoms (DRESS).
Antia C; Persad L; Alikhan A
J Drugs Dermatol; 2017 Oct; 16(10):1043-1046. PubMed ID: 29036260
[TBL] [Abstract][Full Text] [Related]
40. [DRESS syndrome: Report of nine cases].
Ocampo-Garza J; Ocampo-Garza SS; Martínez-Villarreal JD; Barbosa-Moreno LE; Guerrero-González GA; Ocampo-Candiani J
Rev Med Chil; 2015 May; 143(5):577-83. PubMed ID: 26203568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
